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C-type lectinDendritic cells (DC) play a key role in anti-viral immunity. Direct interactions between DC and hepatitis B
virus (HBV) may explain the impaired DC function and the ineffective anti-viral response of chronic HBV
patients resulting in HBV persistence. Here, the interaction between HBV surface antigens (HBsAg) and DC
and the receptor involved were examined by ﬂow cytometry in blood and liver tissue of HBV patients. The in
vitro data showed that the mannose receptor (MR) is involved in HBsAg recognition and uptake by DC. The
presence of HBsAg-positive DC was demonstrated sporadically in blood, but frequently in the liver of HBV
patients. Interestingly, a positive correlation was found between HBsAg positivity and MR expression level in
both liver- and blood-derived DC. These data suggest that in HBV infected patients, MR-mediated interaction
between HBsAg and DC and subsequent impairment of DC predominantly occurs at the main site of infection,
the liver.
© 2009 Elsevier Inc. All rights reserved.Introduction
In the majority of cases, infection with Hepatitis B virus (HBV)
results in self-limiting acute hepatitis, due to a vigorous multi-speciﬁc
T and B cell response (Rehermann and Nascimbeni, 2005). However,
worldwide more than 350 million people are chronically infected
with HBV (WHO, 2004) as the result of a complex interaction between
the replicating virus and an inadequate HBV-speciﬁc immune
response. The underlying mechanism for this ineffective anti-viral
immune response is not clear.
Dendritic cells (DC) are key players in the anti-viral immune
response and form a bridge between innate and adaptive immunity
(Banchereau and Steinman, 1998). They are equipped with special-
ized pattern-recognition receptors, including C-type lectins and Toll
like receptors (Figdor et al., 2002; Thoma-Uszynski et al., 2001). These
receptors enable them to recognize and internalize pathogens
resulting in antigen processing and presentation. The nature of the
pathogen and the receptors involved in pathogen recognition
determine the activation status of the DC, which in turn determines
the quality of the immune response ranging from tolerance to
immunity (Banchereau et al., 2000).logy and Hepatology, Erasmus
m, The Netherlands. Fax: + 31
ltman).
l rights reserved.HBV primarily infects hepatocytes, but both in vitro and in vivo
data indicate that the virus also interacts with DC. HBV-DNA was
demonstrated in isolated blood DC from chronic HBV patients
(Tavakoli et al., 2008; Untergasser et al., 2006; van der Molen et al.,
2004). Recently, we showed that HBV surface antigens (HBsAg) are
internalized by blood-derived myeloid DC (mDC) in vitro, leading to
impaired mDC function (Op den Brouw et al., 2008a). Also several in
vivo studies describe the impaired function of mDC in chronic HBV
patients (Duan et al., 2005; van der Molen et al., 2006; van der Molen
et al., 2004). This impaired mDC function was improved upon viral
load reduction (van der Molen et al., 2006). However, whether in vivo
a direct immune regulatory effect of HBV on DC function exists, which
receptor(s) are involved in this interaction and whether the impaired
function of blood mDC could be explained by circulating HBV and/or
HBsAg is not known.
Several putative binding factors have been described for HBsAg,
such as human serum albumin (Machida et al., 1983), asialoglycopro-
tein receptor (Treichel et al., 1994) and mannose-binding lectin
(Chong et al., 2005), but their exact role in HBV attachment and uptake
remains unclear (Glebe and Urban, 2007). Since HBsAg are glycopro-
teins (Schmitt et al., 2004), the involvement of a C-type lectin in viral
recognitionbyDC seemsplausible. DC are known to express both type I
and type II C-type lectins, including DEC-205 (CD205), mannose
receptor (MR; CD206) andDC-SIGN (CD209), but the expression of the
different C-type lectin family members depends on the DC subset and
differentiation/maturation state (Figdor et al., 2002).
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performed with in vitro generated monocyte-derived DC, which
exhibit functional and phenotypical features of, but are not identical
to, circulating mDC. To unravel the possible interaction between HBV
and mDC in vivo, we investigated the uptake of HBsAg, the receptor
involved and the presence of HBsAg-positive mDC in blood and liver
in vivo.
Results
C-type lectin-mediated endocytosis by mDC increases upon culture
Our previous study on HBsAg internalization by mDC showed an
increased uptake over time (Op den Brouw et al., 2008a), whichmight
be mediated through C-type lectins considering the glycosylation
pattern of HBsAg. Many reports describe C-type lectin expression and
endocytic capacity of monocyte-derived DC, but little is known about
blood-derived mDC. Therefore, the capacity of C-type lectin-mediated
endocytosis of mDC and the culture-induced change in endocytic
capacity was determined with the model substrate dextran-FITC.
Directly after mDC isolation, uptake after 2 h culture in the presence of
dextran-FITC is limited to approximately 15% mDC. Overnight culture
in the presence of GM-CSF, followed by 2 h dextran-FITC uptake,
increased uptake to 36±5% positive mDC (Fig. 1A). As expected,
uptake of dextran-FITC could be blocked by addition of mannan,
which competitively binds the carbohydrate binding site of mannose-
speciﬁc lectins. In addition, dextran-FITC uptake was strongly reducedFig. 1. Lectin-mediated endocytosis of dextran-FITC bymDC increased upon culture. (A)
MDC were analysed for dextran-FITC uptake, either directly after isolation or after O/N
culture. Speciﬁcity was determined by 30 min pre-incubation with mannan. Blanks (–)
represent background ﬂuorescence in the absence of dextran-FITC. Data represent
mean±sd of two independent experiments. (B) O/N cultured mDC were examined for
dextran-FITC uptake after 30 min pre-incubation at 37 °C with different sugars or EGTA.
Data represent mean±SEM of three independent experiments.by addition of D-mannose, D-glucose, D-fructose, fucose, N-acetyl
glucosamine and the calcium chelator EGTA (Fig. 1B). Galactose and
N-acetyl-galactosamine did not inhibit dextran-FITC uptake by mDC,
indicating that e.g. the galactose-speciﬁc asialoglycoprotein receptor
and macrophage galactose-type C-type lectin are not likely to
contribute to lectin-mediated endocytosis by mDC.
C-type lectin expression on mDC
Since both HBsAg (Op den Brouw et al., 2008a) and dextran-FITC
uptake increased after overnight culture, the expression level of
several C-type lectins on mDC was determined by real-time PCR
before and after 18 h of culture. No detectable signal over background
was obtained for L-SIGN, ASGPR1 and Endo-180 (data not shown).
ASGPR2A and B mRNA could be detected in mDC directly after
isolation, while mRNA levels diminished after mDC culture (data not
shown). In contrast to the high level of DC-SIGN mRNA in monocyte-
derived DC ((Kato et al., 2000), data not shown), DC-SIGN mRNA
could not be detected in mDC directly after isolation, although it was
present at very low levels after 18 h of culture (data not shown). Also
MR and DEC-205 mRNA are known to be expressed by monocyte-
derived DC ((Kato et al., 2000), data not shown). In contrast, MR
mRNA levels were undetectable in freshly isolatedmDC, but increased
8- to 32-fold during the 18 h culture period (Figs. 2A, B). DEC-205
mRNA was already present at high levels in mDC directly after
isolation and was 2-fold reduced after culture (Figs. 2A, B). Flow
cytometric analysis also showed an increase of MR-positive mDC after
18 h culture (Fig. 2C). DEC-205 was highly expressed on the mDC cell
surface after isolation, but in contrast to the mRNA expression level,
the protein expression level did not signiﬁcantly change upon culture
(Fig. 2D).
HBsAg internalization is mediated through the MR
The glycosylation pattern of HBsAg, and the increased HBsAg
internalization combined with the increased MR expression upon
mDC culture, indicated the MR as the most likely candidate for HBsAg
uptake. The exact role of the MR in HBsAg internalization was studied
by using mannan as inhibitor and more speciﬁcally, by blocking the
receptor with increasing amounts of neutralizing anti-MR antibodies.
Mannan signiﬁcantly inhibited HBsAg uptake (Fig. 3A). Increasing
amounts of neutralizing anti-MR antibody led to dose-dependent
decrease of HBsAg uptake, with amaximumblock using 10 μg/ml anti-
MR (Fig. 3A). MR neutralization led to a signiﬁcant 2-fold reduction of
HBsAg uptake, compared to both medium control and presence of
control antibody anti-DEC-205 (Fig. 3B; both pb0.007). No signiﬁcant
effect of neutralizing DEC-205 on HBsAg uptake was observed.
Intrahepatic mDC of chronic HBV patients contain HBsAg
To examine whether also in vivo mDC are capable of internalizing
HBsAg, either as subviral particle or as part of the infectious virion, we
studied the presence of HBsAg in blood- and liver-derived mDC of
chronic HBV patients. Blood and liver biopsy samples of patients with
liver diseases other then HBV were used as negative controls. Gating
strategies to identify blood and intrahepatic mDC populations were
similar; except for the FSC/SSC gate since intrahepatic mDC were a bit
smaller and less granular than blood-derived mDC (Fig. 4). Two out of
14 chronic HBV patients clearly contained HBsAg-positive mDC in the
circulation (patient# 7 and 9, Table 1), but in most patients blood-
derived mDC were HBsAg-negative and HBsAg-staining did not
signiﬁcantly differ from control group (Fig. 5A). Strikingly, liver
biopsies from 10 out of 14 HBV patients contained HBsAg-positive
mDC, while no HBsAg positivity was detected in mDC of control liver
biopsies. Paired analysis of blood- and liver-derived mDC of chronic
HBV patients showed signiﬁcantly higher amounts of intrahepatic
Fig. 2. Expression of C-type lectins on mDC. (A) MR and DEC205 mRNA levels relative to GAPDH of mDC of three different donors (c1–3) directly after mDC isolation and after 18 h
culture. (B) Fold change in relative mRNA expression of MR and DEC205 upon culture ofmDC of three different donors (c1–3). (C) Protein expression level of MR on the cell surface of
CD20-BDCA1+mDC before and after 18 h culture. One representative experiment out of three independent experiments is shown. (D) Histogram analysis of DEC205 expression on
mDC before (bold line) and after (ﬁlled graph) 18 h culture. The dotted line represents isotype control. One representative experiment out of three independent experiments is
shown.
86 M.L. Op den Brouw et al. / Virology 393 (2009) 84–90HBsAg-positive mDC (Fig. 5A; 3.8±1% intrahepatic vs 1.4±0.3%
blood-derived (mean±SEM) HBsAg-positive mDC; p=0.047). The
number of HBsAg-positive mDC found in the liver varied between
patients and positively correlated with the number of HBsAg-positive
hepatocytes, the main target of HBV (Table 1, Fig. 5B, p=0.0017).
In vivo presence of HBsAg in mDC correlates with MR expression
Since HBsAg is abundantly present in both blood and liver of
chronic HBV patients, the HBsAg concentration cannot explain the
difference in HBsAg uptake between blood- and liver-derived mDC.
Thus the ligand speciﬁcity and/or the endocytic capacity should differ
between blood- and liver-derived mDC. The in vitro experiments
demonstrated a key role for MR in HBsAg uptake, but upregulation of
this receptor by cell culture was a prerequisite for HBsAg internal-
ization. Therefore, the MR expression level of blood- and liver-
derived mDC of chronic HBV patients was studied. Intrahepatic mDC
showed a signiﬁcantly 4-fold higher MR expression compared to
peripheral blood-derived mDC (Fig. 6A; 8.9±1.7% vs 2.2±0.8% MR-
positive mDC; p=0.034). When individual patients were studied, a
signiﬁcant positive correlation was found between HBsAg positivity
and MR expression level in both liver- and blood-derived mDC (Fig.
6B).
Discussion
DC are professional antigen-presenting cells with a critical role in
the initiation and direction of anti-viral immune responses (Bancher-
eau and Steinman, 1998). C-type lectins on DC recognize glycan
structures expressed on pathogens, resulting in pathogen internali-
zation followed by processing and antigen presentation on MHC
molecules (Figdor et al., 2002). The present study provides insight in
the level of interaction between mDC and HBsAg and the role of theMR in this interaction. We demonstrate that the MR is involved in the
uptake of HBsAg by mDC in vitro and also show HBsAg-positive mDC
in HBV infected individuals ex vivo. While only a minority of the
chronic HBV patients contained HBsAg in blood-derived mDC, a
signiﬁcant number of liver-derived mDC of these patients contained
HBsAg, which correlatedwithMR expression. These data demonstrate
that HBV interacts with mDC in vivo, especially at the main site of
infection, i.e. the liver, and point towards a crucial role for MR in this
interaction.
Most circulating blood mDC were found to be negative for the MR,
which was reﬂected by the lack of HBsAg ex vivo and the relative low
capacity to take up dextran-FITC as a model substrate for lectin-
mediated endocytosis. This low lectin-mediated endocytic capacity is
in line with data of Kato et al. and in sharp contrast to the high
dextran-FITC uptake by in vitro generated monocyte-derived DC
(Kato et al., 2000). Although it is known that expression of e.g. cell
surface molecules such as C-type lectins varies (MacDonald et al.,
2002), monocyte-derived DC are frequently used as a model for mDC.
A clear example is the C-type lectin DC-SIGN: highly expressed on
monocyte-derived DC but not present on circulating blood mDC, as
shown before (MacDonald et al., 2002) and conﬁrmed here by real-
time PCR analysis. Culture of mDC in the presence of GM-CSF
enhanced dextran-FITC uptake and sugar inhibition studies indicated
that mannose-speciﬁc receptor mediated endocytosis mainly con-
tributed to this binding. Real-time PCR combined with ﬂow
cytometric analysis on the expression of C-type lectins, indicated a
role for the MR in binding and uptake of HBsAg by mDC. Blocking
experiments with mannan and, more speciﬁcally, a neutralizing
antibody against the MR conﬁrmed the role of MR in HBsAg uptake by
mDC in vitro.
The MR expression on the cell surface of cultured blood-derived
mDC and intrahepatic mDC, but not on circulating mDC in whole
blood, likely reﬂects the difference in differentiation state and
Fig. 3. In vitro HBsAg uptake by mDC is mediated through the MR. HBsAg uptake after
O/N culture was measured by ﬂow cytometry. Speciﬁcity was determined by 30 min
pre-incubation with mannan, increasing amounts of neutralizing anti-MR antibody, or
control anti-DEC205 antibody. Negative controls were incubated without HBsAg (−) or
with HBsAg at 4 °C. Data demonstrate a representative experiment (A) and the
quantiﬁcation of eight independent experiments (B) (mean±SEM, ⁎⁎pb0.007, paired t
test against both medium control and anti-DEC205).
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tissue. Plausibly, mDC are recruited to the site of infection, acquire the
MR on the cell surface as a result of migration-induced differentiation
and subsequently internalize HBV and/or HBsAg. Whether MR
expression is inﬂuenced by liver inﬂammation could not be
determined, since control patients were also presented with liver
inﬂammation, as indicated by the elevated alanine aminotransferase
levels. A more deﬁnite answer could come from analysis of steady
state livers, but without a clinical need to obtain a liver biopsy such
material is rarely available.
The expression of HBsAg by infected hepatocytes in almost all
biopsy samples taken from chronic HBV patients included in this
study and the correlation between the level of HBsAg-positive
hepatocytes and -intrahepatic mDC, not only indicates that the biopsy
sample was taken at a site of active HBV infection, but also shows that
the virus-DC interaction takes place at the site of infection.
Next to the MR, other classes of C-type lectins have been
described to interact with HBsAg. Chong et al. have demonstrated
that HBsAg can interact with soluble mannose-binding lectin
leading to complement activation, which could contribute to viral
clearance by enhanced phagocytosis (Chong et al., 2005) and may
explain the potential contribution of mannose-binding lectin
polymorphisms in HBV disease progression (reviewed in (Brown
et al., 2007)). Furthermore, the asialoglycoprotein receptor,
expressed by e.g. liver sinusoidal endothelial cells (LSEC) and
hepatocytes, has been shown to interact with HBV virions through
the preS1 domain of HBsAg (Treichel et al., 1994). Since LSEC are
also known to express MR (Elvevold et al., 2008), the MR could play
a role in the capture and transportation of HBV virions across the
liver endothelium to infect adjacent hepatocytes, comparable to themodel proposed by Breiner et al., (2001). Whether the MR could
also play a role in the infection of hepatocytes is not known. In this
study we observed that approximately 10% of hepatocytes express
the MR (data not shown), possibly contributing to the capture of
HBsAg and/or HBV virions.
Although C-type lectin DEC-205 belongs to the same family as the
MR and is highly expressed onmDC, it does not interact with HBsAg. A
difference in ligand speciﬁcity is the obvious explanation, although
DEC-205 ligands still need to be determined (Shrimpton et al., 2009).
More surprisingly is the observed recognition of HBsAg byMR, but not
by DC-SIGN (Op den Brouw et al., 2008b). Whereas most pathogens
recognized by the MR also show interaction with DC-SIGN, e.g.
Mycobacterium tuberculosis and HIV (Robinson et al., 2006), the
subtle differences between ligand speciﬁcity of DC-SIGN and MR,
namely the recognition of complex mannose structures versus end-
standing mannose residues (Cambi et al., 2005), leads to major
differences in HBsAg recognition.
In contrast to pathogen recognition by e.g. Toll like receptors,
interaction with C-type lectins DC-SIGN and MR does not induce DC
maturation (van Kooyk, 2008). Thus the MR-mediated HBsAg uptake
in the absence of a Toll like receptor signal may lead to HBV/HBsAg-
speciﬁc tolerance, which could be further supported by the
microenvironment of the liver. From unpublished observations we
know that neither HepG2.2.15-derived HBV nor HBsAg are able to
induce DC maturation. Moreover, both HBV and HBsAg can directly
reduce the immunogenicity of DC in vitro, which indicates a possible
immune escape mechanism of HBV by the virus itself and/or by the
production of HBsAg (Beckebaum et al., 2003; Op den Brouw et al.,
2008a). Although there are conﬂicting data published, several
studies demonstrated an impaired DC function in chronic HBV
patients, which could at least partially explain HBV persistence
(Beckebaum et al., 2002; Duan et al., 2005; Tavakoli et al., 2008;
Tavakoli et al., 2004; van der Molen et al., 2006; van der Molen et al.,
2004). This immune regulatory effect of HBV is supported by the fact
that an adefovir-induced viral load reduction strongly increased the
capacity of mDC of chronic HBV patients to produce IL-12 and to
stimulate T cell activation (van der Molen et al., 2006). The ﬁnding
that only two out of 14 chronic HBV patients demonstrated HBsAg-
positive mDC in blood, is comparable to a study by Untergasser et al.,
showing HBV-DNA positive mDC in one out of ﬁve patients
(Untergasser et al., 2006). In contrast, two other studies show
HBV-DNA in mDC of either half the patient population (van der
Molen et al., 2004) or even in 10 out of 12 patients (Tavakoli et al.,
2008). Diversity between patient cohorts included in each study
might explain part; another important difference is the detection
method of HBV.
In conclusion, the present study for the ﬁrst times shows the
involvement of the MR in binding of HBsAg. The immune competence
of chronic HBV patients combined with the relative low level of
interaction between HBV/HBsAg and mDC in peripheral blood
indicates that HBV especially interferes with mDC function in the
liver. Whether the MR is directly involved in the immune regulatory
effects of HBV and HBsAg remains to be elucidated.
Materials and methods
Isolation of mDC from peripheral blood
All healthy controls gave written informed consent before blood
donation. MDC (BDCA1+) were isolated from healthy control blood
using anti-BDCA1-PE and PE-conjugated microbeads (Miltenyi Biotec,
Bergisch Gladbach, Germany) as described previously (van der Molen
et al., 2004). MDC purity and viability were determined by ﬂow
cytometry (FACScalibur, Becton, Dickinson and Company (BD),
Franklin Lakes, NJ). Gated on viable cells, the purity of isolated mDC
ranged from 85 to 95%. MDC were cultured in RPMI 1640 (Bio
Fig. 4. Flow cytometric analysis of blood- and liver-derived mDC. Blood and liver biopsy samples of patients with chronic HBV and control patients with non-HBV related liver
diseases were measured by ﬂow cytometry after staining for anti-CD45, anti-CD14, anti-CD20, anti-BDCA1 and anti-HBsAg. The left panel shows the mDC gating strategy of a
representative blood sample; the right panel shows a representative liver biopsy sample. MDC are identiﬁed as CD45+CD14−CD20−BDCA1+ within this population the percentage
HBsAg-positive cells was determined as shown for a representative control (patient# 23) and HBV patient (patient# 5).
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Logan, UT), penicillin (50 IU/ml), streptomycin (50 μg/ml) and GM-CSF
(500 U/ml; Leucomax, Novartis Pharma, Arnhem, The Netherlands).Table 1
HBsAg and MR levels of blood- and liver-derived myeloid DC and hepatocytes.
Patient Blood mDC Liver mDC Hepatocytes
Total
events
HBsAg+
(%)
MR+
(%)
Total
events
HBsAg+
(%)
MR+
(%)
Total
events
HBsAg+
(%)
1 630 0.2 0.3 2318 2.8 3.5 22692 18.3
2 254 1.3 0.0 310 7.1 20.3 17989 16.9
3 484 1.9 11.8 915 0.3 9.3 9468 3.1
4 340 1.2 1.2 1200 0.1 5.1 13628 1.0
5 310 1.0 1.6 1668 4.0 5.8 9107 26.3
6 756 0.8 1.6 166 4.8 12.7 10233 18.2
7 1055 3.1 1.7 635 0.8 4.7 7557 16.4
8 1143 1.0 1.0 1351 3.0 5.9 20609 24.9
9 421 3.8 4.3 2349 0.8 2.4 16720 14.3
10 1240 0.6 1.0 1168 1.9 2.3 15227 0.8
11 1736 0.6 1.2 160 14.4 14.4 1360 44.5
12 400 1.0 1.8 362 3.3 20.7 14045 3.2
13 416 1.9 2.2 727 5.0 12.5 16002 26.5
14 141 0.7 1.4 1393 5.5 5.6 12737 73.4
15 146 0.7 10.6 367 1.1 6.8 9323 0.1
16 730 1.9 3.3 858 1.3 4.2 20330 0.1
17 546 1.1 4.6 564 1.8 10.3 13391 0.1
18 1000 0.7 1.8 356 1.1 12.9 12734 0.2
19 576 0.2 5.7 1350 0.5 7.2 16689 0.3
20 311 0.3 1.6 230 1.3 18.3 8227 0.2
21 624 1.3 1 1641 1.5 2.6 16194 0.5
22 484 1.9 6.4 1343 0.3 5.2 20143 0.2
23 429 0.7 1.6 1849 0.5 3.7 11329 0.4Lectin-mediated endocytosis
MDC were directly used to study the endocytic capacity or ﬁrst
cultured for 18 h, followed by 2 h incubation in the presence or absence
of dextran-FITC (100 μg/ml; 40.000 MW, Molecular Probes, Invitrogen,
Carlsbad, CA). For HBsAg binding and uptake, mDC were incubated for
18 h with recombinant HBsAg (2 μg/ml, kindly provided by M. van
Roosmalen, bioMérieux, Boxtel, the Netherlands) (Op den Brouw et al.,
2008a). Antigen uptakewas stopped by coldwash in PBS containing 1%
FCS and 0.02% NaN3. HBsAg was stained by intracellular staining with
anti-HBsAg-FITC (Acris Antibodies GmbH, Hiddenhausen, Germany) as
described before (Op den Brouw et al., 2008a) and cells weremeasured
by ﬂow cytometry. This protocol detects both surface bound and
internalized HBsAg. Lectin-mediated endocytosis was inhibited by
30 min pre-incubation at 37 °C with mannan (100 μg/ml; Sigma-
Aldrich, St. Louis, MO), D-mannose, D-glucose, D-fructose, D-galactose,
fucose, N-acetyl glucosamine, N-acetyl galactosamine (50 mM; Sigma-
Aldrich), EGTA (20 mM; Sigma-Aldrich), neutralizing anti-MR (1–
20 μg/ml; clone 19.2, BD) or neutralizing control antibody anti-DEC205
(10 μg/ml; cloneMG38, AbDSerotec, Kidlington, UK). Negative controls
were incubated without antigen or with antigen at 4 °C.
Lectin expression
MDC were lysed in Trizol (Sigma-Aldrich) directly after isolation
and after 18 h of culture. RNA was precipitated with 75% ethanol and
isolated using Micro RNAeasy silica columns (Qiagen, Venlo, The
Netherlands). cDNA was prepared using AMV reverse transcriptase
according to the manufacturer's protocol (Promega, Madison, WI).
Real-time PCR (MyIQ, Biorad, Hercules, CA) was performed using
Fig. 6. Positive correlation between presence of HBsAg andMR expression level inmDC of
chronicHBVpatients. (A)MRcell surfaceexpressionof blood- and liver-derivedmDCof14
chronic HBV patients was measured by ﬂow cytometry (mean±SEM MR-positive mDC,
⁎pb0.05). (B) The correlation betweenHBsAgpositivity andpresenceofMRonblood- and
liver-derived mDC was determined with the Spearman test (r=0.62, p=0.0005).
Fig. 5. HBsAg is mainly detected in liver-derived mDC. (A) Blood- and liver-derived
mDC populations of 14 chronic HBV and 9 control patients were assessed for presence
of HBsAg (⁎pb0.05). (B) Liver biopsy samples were used to determine the presence of
HBsAg-positive hepatocytes, gated on FSC/SSC and CD45 negativity. The correlation
between presence of HBsAg in hepatocytes and intrahepatic mDC was determined with
the Spearman test (r=0.76, p=0.0017).
Table 2
Patient characteristics.
Patient # Age (yr) Sex Liver
disease
Genotype Serum viral
loada,b
Serum ALTc
(U/l)
1 30 M HBV D 4.17⁎103 38
2 45 M HBV D 5.12⁎109 155
3 32 M HBV D 6.46⁎104 78
4 26 M HBV C 8.48⁎108 444
5 55 M HBV A 3.05⁎106 58
6 29 M HBV D 2.50⁎107 77
7 31 M HBV ND 4.34⁎103 28
8 39 F HBV D 7.16⁎105 30
9 27 F HBV ND 3.41⁎103 49
10 40 M HBV ND 2.25⁎1010 101
11 39 F HBV B 1.57⁎109 35
12 22 F HBV D 2.14⁎103 86
13 32 F HBV ND 2.37⁎108 46
14 28 F HBV ND 2.27⁎104 38
15 55 M HCV 3 ND 160
16 64 F HCV 1 9.86⁎105 182
17 48 M HCV 1 3.58⁎107 16
18 42 M LTxd NA NA 63
19 41 M Other NA NA 43
20 45 M HCV 4 ND 59
21 22 M HCV 1 2.55⁎107 43
22 36 F HCV 1 8.17⁎106 78
23 42 M HCV 1 2.84⁎106 92
NA, not applicable; ND, not determined.
a HBV DNA and HCV RNA are given in geq/ml.
b Within 12 weeks of biopsy time point.
c Within 2 weeks of biopsy time point.
d Due to primary sclerosing cholangitis.
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GGTGCTAAGCAGTTGGTGGTG-3′), DEC-205 (F: 5′-CCCTATGTCTG-
CAGGAAACCA-3′; R: 5′-TGCATCACAGCGGGTATCTG-3′) and MR (F:
5′-GTCTTGGGCCACAGGTGAA-3′; R: 5′-AAGGCGTTTGGATAGCCACA-
3′) with iQ SYBR Green supermix (Biorad) for 40 cycles and gene
expressionwas calculated using theΔΔCTmethod. Protein expression
levels of MR and DEC-205 were determined by ﬂow cytometry after
staining with anti-BDCA1-PE (clone AD5-8E7, Miltenyi), anti-CD20-
PerCP (BD), anti-CD205-FITC (cloneMG38, eBioscience, SanDiego, CA)
and anti-CD206-APC (clone 19.2, BD) in PBS containing 1% FCS and
0.02% NaN3.
HBsAg-staining on patient-derived blood and liver tissue
Blood and percutaneous needle liver biopsies were obtained from
14 chronic HBV patients and 9 non-HBV patients with other liver
diseases as part of their diagnostic evaluation. Control patients were
negative for markers of prior HBV exposure. The medical ethical
committee of the Erasmus MC declared to have no objections against
the use of excess patient material and all patients gave informed
consent before inclusion. Patient characteristics are given in Table 2.
Excess tissue from liver biopsy samples was collected in RPMI and
grinded through a 70 μM nylon cell strainer (BD) to obtain a single
cell suspension of mononuclear cells, which were stained with a
combination of anti-BDCA1-PE, anti-CD14-PerCP (clone MOP9, BD),
anti-CD20-PaciﬁcBlue (clone 2H7, eBioscience), anti-CD45-AmCyan
(clone 2D1, BD) and anti-CD206-APC followed by intracellular
staining with anti-HBsAg-FITC. Cells were measured by 8-color
ﬂow cytometry (FACSCanto II, BD) and analyzed with BD FACSDiva
software. MDC were identiﬁed as CD45+CD14−CD20−BDCA1+ and
assessed for the presence of HBsAg and expression of MR. Only
measurements with an mDC population of at least 100 events wereincluded; background HBsAg-staining in control non-HBV patients
was never above 2%. Hepatocytes were gated on forward/sideward
scatter and CD45 negativity and assessed for presence of HBsAg.
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